A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome

NCT04718844 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

44

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-transfusion-dependent Thalassemia
Low Risk Myelodysplastic Syndrome
Very-Low Risk Myelodysplastic Syndrome

Interventions

DRUG: SLN124
DRUG: Placebo

Sponsor

Silence Therapeutics plc